Latest / The Well-Built Life / Neuronic's RLT: Revolutionizing Cognitive Health
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:06Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. Welcome to The Well-Built Life, where
- 0:25Speaker 1: we explore the latest in fitness, nutrition, and cognitive health.
- 0:29Speaker 1: I am Rachel, and joining me is Thomas. Today, we
- 0:34Speaker 1: are diving into some groundbreaking work being done in cognitive
- 0:37Speaker 1: health treatments. Let's start with how two visionaries, Liam, Pyring,
- 0:41Speaker 1: and Marvin, have been using red light therapy to tackle
- 0:45Speaker 1: issues like Alzheimer's and ADHD.
- 0:48Speaker 2: Exactly, Rachel. Liam and Marvin have taken an innovative approach
- 0:52Speaker 2: with neurotic red light therapy. RLT, they started with a
- 0:56Speaker 2: background in PBM, which stands for photobiomodulation. You know, it's
- 1:00Speaker 2: the use of specific wavelengths of light to help enhance
- 1:03Speaker 2: neuron function and mitigate cognitive decline. Let's break down how
- 1:07Speaker 2: they got to where they are. Right.
- 1:10Speaker 1: Liam and Marvin's journey began around 2020 when they dove
- 1:13Speaker 1: into initial development and prototyping of their devices. They came
- 1:18Speaker 1: up with the Neuronic Light and the Neuroradiant 1070. These
- 1:22Speaker 1: are quite advanced, aren't they?
- 1:23Speaker 2: Absolutely. And it's not just about the technology. The initial
- 1:27Speaker 2: clinical trials from MCI and Alzheimer's disease in 2022 showed
- 1:32Speaker 2: some really impressive results. For example, there were improvements in
- 1:37Speaker 2: cognitive function scores like the MOC and CHEM-S2, with significant
- 1:41Speaker 2: accuracy and reaction time enhancements.
- 1:43Speaker 1: That's quite the progress. What about their work with ADHD?
- 1:48Speaker 1: Marvin mentioned they had a pretty robust trial in 2023. Indeed.
- 1:53Speaker 2: They launched a trial focusing on ADHD, where they found
- 1:56Speaker 2: significant improvements in response inhibition with fewer false alarms. It's
- 2:01Speaker 2: really intriguing how precise effects can be on such a
- 2:04Speaker 2: complex condition.
- 2:05Speaker 1: The initial findings are promising, but how do they explain
- 2:09Speaker 1: the mechanisms behind it? What's the magic of light therapy here?
- 2:13Speaker 2: Great question. PBM works by increasing mitochondrial activity and cytochrome
- 2:19Speaker 2: C oxidase, CTO oxidation. which enhances neuronal energy supply and
- 2:24Speaker 2: blood flow. It's a fascinating balance of science and clinical application.
- 2:29Speaker 2: But let's not get too carried away. Therese still room
- 2:32Speaker 2: for more research and validation.
- 2:34Speaker 1: Absolutely. Speaking of which, how do their findings stack up
- 2:39Speaker 1: against traditional treatments?
- 2:40Speaker 2: That's an excellent point. Traditional psychiatric treatments and cognitive therapies
- 2:46Speaker 2: are still dominant, and while RLTO shows promise, comparative effectiveness
- 2:50Speaker 2: studies are crucial. We need more data to fully understand
- 2:54Speaker 2: how each approach fits into the broader picture of mental
- 2:57Speaker 2: health treatments.
- 2:58Speaker 1: And don't forget, the devices are already on the market.
- 3:02Speaker 1: How are they performing in the commercial space?
- 3:04Speaker 2: They have been well-received, with positive user reactions and a
- 3:08Speaker 2: target audience that includes individuals with cognitive decline and anxiety.
- 3:14Speaker 2: But there are also healthcare professionals curious about integrating these
- 3:18Speaker 2: devices into their practices.
- 3:19Speaker 1: Moving forward, What are the key areas of focus for Neuronic?
- 3:24Speaker 2: Looking ahead, they are focusing on integrating AI for personalized
- 3:29Speaker 2: treatment plans. We will also see more longitudinal studies to
- 3:33Speaker 2: determine the long-term safety and effects of these therapies, as
- 3:37Speaker 2: well as sustainability and user-friendly designs.
- 3:40Speaker 1: It sounds like a dynamic and evolving field. Any unsolved
- 3:44Speaker 1: questions or challenges they are currently facing?
- 3:47Speaker 2: Definitely. They are grappling with finding the optimal dosage and
- 3:52Speaker 2: frequency for different conditions, ensuring quality control, and obtaining regulatory approvals.
- 3:58Speaker 2: Therese also the challenge of getting insurance coverage, which will
- 4:02Speaker 2: be crucial for broader patient access.
- 4:04Speaker 1: Thanks, Thomas. As we wrap up, it's clear that neuronic's
- 4:07Speaker 1: work is paving the way for new possibilities in cognitive health.
- 4:12Speaker 1: We are excited to see how this innovative approach continues
- 4:15Speaker 1: to develop in the future. Join us next time on
- 4:18Speaker 1: The Well-Built Life. as we delve into more fascinating health
- 4:21Speaker 1: and wellness topics.
- 4:22Speaker 2: Until then, stay well and keep exploring.
- 4:25Speaker 1: As we delve into the nitty-gritty of neurotic RLTS effectiveness,
- 4:31Speaker 1: let's start by looking at the key mechanisms underlying this therapy. Thomas,
- 4:36Speaker 1: can you explain how the photobiomodulation, PBM, works and what
- 4:41Speaker 1: effects it has on the brain?
- 4:42Speaker 2: Absolutely, Rachel. At its core, Neuronic RLT uses red and
- 4:47Speaker 2: near-infrared light to stimulate cellular metabolism and improve neuronal function.
- 4:52Speaker 2: The light increases the activity of mitochondrial oxidative enzymes, particularly
- 4:57Speaker 2: cytochrome C oxidase CCO, which in turn enhances AT production.
- 5:03Speaker 2: This boost in energy helps neurons to function more efficiently,
- 5:07Speaker 2: leading to improved cognitive performance and mental clarity.
- 5:10Speaker 1: That sounds fascinating, Thomas. Can you talk about some of
- 5:14Speaker 1: the clinical data that supports these claims? We have heard
- 5:17Speaker 1: improvements in things like working memory accuracy and reaction times.
- 5:21Speaker 2: Yes, exactly. In fact, we have several case studies that
- 5:25Speaker 2: back these claims. For instance, one study showed a 56%
- 5:29Speaker 2: accuracy improvement and a 6% increase in accuracy alongside a
- 5:34Speaker 2: 17% faster response time in the active treatment group compared
- 5:37Speaker 2: to the sham treatment. Another case highlighted significant improvements in
- 5:41Speaker 2: the Montreal Cognitive Assessment. MoC scores and the KMS2 for
- 5:46Speaker 2: patients with mild cognitive impairment and Alzheimer's disease. This data
- 5:51Speaker 2: is compelling and suggests that RLT could be a valuable
- 5:55Speaker 2: addition to cognitive health treatments.
- 5:57Speaker 1: And what about the debate over optimal dosage and frequency?
- 6:01Speaker 1: It seems like to raise a lot of discussion around
- 6:04Speaker 1: how often and how much light is needed for the
- 6:07Speaker 1: best results.
- 6:08Speaker 2: Indeed, to reason nuanced debate here. The optimal dosage and
- 6:12Speaker 2: frequency can vary widely depending on the condition, the individual,
- 6:17Speaker 2: and the device being used. For example, for mild cognitive impairment,
- 6:21Speaker 2: some studies suggest daily sessions for a month, while for ADHD,
- 6:26Speaker 2: the frequency might be higher, perhaps every other day for
- 6:30Speaker 2: a shorter duration. This variability highlights the need for personalized
- 6:34Speaker 2: treatment plans, which is an area where AI could significantly
- 6:38Speaker 2: enhance the RLT experience.
- 6:40Speaker 1: That's a great point. And speaking of individuals, we should
- 6:43Speaker 1: also consider the stakeholders involved. Investors, researchers, and patients all
- 6:50Speaker 1: have different needs and expectations. How do these groups interact
- 6:55Speaker 1: and influence the development and implementation of RLTT?
- 6:59Speaker 2: Absolutely. The relationships between these stakeholders are crucial. Investors are
- 7:04Speaker 2: looking for validation of the technology. Researchers aim for rigorous
- 7:08Speaker 2: clinical trials. and patients want effective, safe therapies. The founder
- 7:13Speaker 2: Liam Pyring and Marvin have been key in driving the
- 7:16Speaker 2: initial development. But as we scale, it's important to balance
- 7:20Speaker 2: corporate interests with scientific rigor and patient safety. Collaboration between
- 7:25Speaker 2: these groups ensures that the therapy evolves in a meaningful
- 7:29Speaker 2: and effective way.
- 7:30Speaker 1: And what about the comparison with traditional treatments? How does
- 7:35Speaker 1: RLT stack up against medications? or cognitive therapies?
- 7:39Speaker 2: That's a valid question. Traditional treatments often come with known
- 7:43Speaker 2: side effects and risks, whereas RLT is generally seen as
- 7:47Speaker 2: a safer option with fewer adverse effects. However, Therese still
- 7:52Speaker 2: debate about its comparative effectiveness. For conditions like ADHD, we
- 7:57Speaker 2: see improvements, but for others, traditional treatments might be more
- 8:01Speaker 2: established and widely used. The key will be to conduct
- 8:05Speaker 2: more large-scale, long-term studies to establish comprehensive comparisons.
- 8:10Speaker 1: Speaking of comparisons, the optimal dosage and frequency remain open questions.
- 8:17Speaker 1: How do you see these being resolved in the near future?
- 8:20Speaker 2: That's an interesting dynamic, Rachel. Future research will likely focus
- 8:24Speaker 2: on personalized medicine approaches using data from devices and patient
- 8:29Speaker 2: feedback to fine-tune dosages. AI could play a big role
- 8:33Speaker 2: here by analyzing patterns and providing personalized recommendations. Additionally, more
- 8:39Speaker 2: longitudinal studies will help address these questions, ensuring that treatment
- 8:44Speaker 2: regimens are both effective and safe.
- 8:46Speaker 1: All of this sounds like a promising mix of technology
- 8:49Speaker 1: and therapeutic benefits. It's clear that Neuronic RLT is making
- 8:53Speaker 1: significant strides. We will be eager to see how it
- 8:56Speaker 1: continues to evolve. Thomas Any last thoughts on where we
- 9:01Speaker 1: should focus our attention next?
- 9:03Speaker 2: Absolutely. We should continue to focus on optimizing treatment plans,
- 9:07Speaker 2: ensuring quality control, and addressing safety concerns. The integration of
- 9:12Speaker 2: AI could bring a significant leap forward in personalization and effectiveness.
- 9:17Speaker 2: And of course, securing broader insurance coverage will be key
- 9:21Speaker 2: for wider patient access.
- 9:22Speaker 1: As we move past the initial excitement of Neuronic RLTS success,
- 9:27Speaker 1: let's focus on the deeper waters. Thomas, can you delve
- 9:31Speaker 1: into the potential long-term safety issues and how they might
- 9:34Speaker 1: impact individual responses?
- 9:36Speaker 2: Absolutely, Rachel. The safety paradox is quite real here. While
- 9:40Speaker 2: initial trials are promising, there are concerns about prolonged exposure.
- 9:45Speaker 2: Some researchers speculate that cumulative exposure to red and near-infrared
- 9:49Speaker 2: light might have unforeseen effects on the human body, especially
- 9:52Speaker 2: considering the brain's vulnerability. How might these safety issues intertwine
- 9:57Speaker 2: with individual variability?
- 9:59Speaker 1: That's a great point. Individual variability is another factor we
- 10:03Speaker 1: need to navigate. Take genetic predispositions or different baseline health conditions,
- 10:09Speaker 1: they could all affect how someone responds to RLT. What
- 10:13Speaker 1: do you think the impact might look like in practice?
- 10:16Speaker 2: Exactly, which brings up an interesting contradiction. We see this
- 10:20Speaker 2: in many therapies. For instance, what works for one patient
- 10:24Speaker 2: might not for another. Consider the ADHD trial, where 51%
- 10:29Speaker 2: improvement in response inhibition was reported, yet responses varied wildly
- 10:34Speaker 2: among participants. This highlights the need for a nuanced approach,
- 10:38Speaker 2: maybe even personalization of treatment plans.
- 10:41Speaker 1: Right. Speaking of personalization, how does integrating AI come into
- 10:46Speaker 1: play here? Isn't AI supposed to help create more tailored
- 10:50Speaker 1: treatment options?
- 10:51Speaker 2: Indeed, AI offers a promising avenue. By analyzing vast datasets,
- 10:56Speaker 2: we could develop algorithms that predict how individuals will respond
- 11:00Speaker 2: based on their specific profiles. For example, using machine learning
- 11:04Speaker 2: to adjust the dosage and frequency dynamically based on real-time
- 11:08Speaker 2: biometric data. This could optimize outcomes while mitigating side effects.
- 11:13Speaker 1: That's wild when you look at the raw numbers. Let's
- 11:16Speaker 1: say a user has a genetic predisposition to certain cognitive functions.
- 11:22Speaker 1: How do we ensure that the device adapts to their
- 11:24Speaker 1: unique needs?
- 11:25Speaker 2: That's exactly the challenge. We need robust quality control at
- 11:29Speaker 2: every step. From the manufacturing process to the actual use
- 11:33Speaker 2: of the device, every component should be meticulously monitored. This
- 11:38Speaker 2: not only ensures safety but also maintains the effectiveness of
- 11:41Speaker 2: the treatment. Regular updates and feedback loops from users would
- 11:46Speaker 2: help refine the AI-driven systems over time.
- 11:48Speaker 1: And if we get this right, we can truly revolutionize
- 11:51Speaker 1: cognitive health treatments. But it's all about that fine balance
- 11:56Speaker 1: between pushing the boundaries and ensuring safety. Any final thoughts? Thomas?
- 12:02Speaker 2: Yes, I think it's crucial to continue the research, but
- 12:05Speaker 2: with a dose of caution. We need both depth in
- 12:08Speaker 2: our data collection. and breadth in clinical trials to address
- 12:12Speaker 2: the diverse needs of patients. The integration of AI could
- 12:15Speaker 2: be the key that helps us tailor those experiences effectively.
- 12:19Speaker 2: We are not just playing with a new tool, we
- 12:22Speaker 2: are potentially altering individual lives, one brain at a time.
- 12:25Speaker 1: So, we have seen the impressive preliminary results, but as
- 12:29Speaker 1: we look ahead, what are some of the key questions
- 12:32Speaker 1: we need to consider when it comes to the optimal
- 12:34Speaker 1: dosage and frequency of RLT treatments.
- 12:37Speaker 2: Exactly, and that's such a critical point. For instance, Dr.
- 12:41Speaker 2: Paring mentioned that the protocols might need to be adjusted
- 12:45Speaker 2: based on the individual's condition and response. Think about it
- 12:49Speaker 2: this way. Just as different people require different amounts of medication,
- 12:53Speaker 2: the same might apply to RLT treatments.
- 12:56Speaker 1: Right, and we already know that frequency can play a
- 12:59Speaker 1: big role. Some patients might benefit from daily sessions. while
- 13:04Speaker 1: others might see results with just a couple of times
- 13:07Speaker 1: a week.
- 13:07Speaker 2: That's the kind of nuance we need to explore further.
- 13:10Speaker 2: For example, let's consider the role of AI in customizing
- 13:14Speaker 2: these dosages and frequencies. AI could potentially analyze data from
- 13:19Speaker 2: millions of cases, pinpointing the exact parameters that work best
- 13:23Speaker 2: for each patient.
- 13:24Speaker 1: And that's where the real breakthrough lies, isn't it? Harnessing
- 13:29Speaker 1: AI to not only assess the patient's condition, but also
- 13:32Speaker 1: to adapt therapy in real time. It's like having a
- 13:36Speaker 1: personalized plan for each individual.
- 13:38Speaker 2: Exactly like tailoring a diet to a specific body type.
- 13:42Speaker 2: But let's not forget, while AI holds promise, we still
- 13:45Speaker 2: need robust safety protocols. What kind of side effects should
- 13:49Speaker 2: we be monitoring, and how do we ensure that patients
- 13:52Speaker 2: receive the correct and safe treatment regimen?
- 13:54Speaker 1: That's a good segue into our next point about long-term safety.
- 13:59Speaker 1: The truth is, We don't have enough data yet. We
- 14:03Speaker 1: need long-term studies to understand the potential risks and benefits
- 14:07Speaker 1: over an extended period.
- 14:09Speaker 2: True, and that's why it's important to have a multifaceted approach.
- 14:13Speaker 2: We should be looking at both short-term and long-term effects,
- 14:17Speaker 2: including any potential cumulative impacts from prolonged use.
- 14:21Speaker 1: Speaking of long-term effects, to raise also the issue of
- 14:24Speaker 1: regulatory hurdles, how do we navigate the complex landscape of approvals,
- 14:29Speaker 1: and certifications to ensure these devices can be used widely.
- 14:33Speaker 2: Absolutely. Regulatory bodies will want to see comprehensive data, not
- 14:38Speaker 2: just short-term improvements, but also long-term safety profiles. It's a
- 14:43Speaker 2: balancing act between innovation and ensuring public safety.
- 14:46Speaker 1: And while we are on the topic of access, to
- 14:49Speaker 1: raise always the challenge of making these devices affordable and
- 14:52Speaker 1: available to everyone. How do we bridge the gap between
- 14:56Speaker 1: high-tech therapeutic devices and everyday needs?
- 14:59Speaker 2: Great question. Perhaps a phased approach where initial applications see
- 15:03Speaker 2: the most advanced and expensive technology, then gradually roll out
- 15:07Speaker 2: more affordable versions as the technology matures. This way, we
- 15:12Speaker 2: can start with a small but significant cohort while ensuring
- 15:15Speaker 2: broader access eventually.
- 15:17Speaker 1: Exactly phased rollouts, enhanced user experience, and robust quality controls.
- 15:23Speaker 1: It's all about building a sustainable and scalable model that
- 15:26Speaker 1: benefits the most people. Let's wrap this up knowing that
- 15:30Speaker 1: there is a lot of work to do, but the
- 15:32Speaker 1: potential rewards are well worth the effort. As we look
- 15:35Speaker 1: towards the strategic implications and future outlook of Neuronic RLTA,
- 15:40Speaker 1: it's fascinating to consider how this technology will impact both
- 15:43Speaker 1: clinical and home-based treatments. Thomas, what do you think the
- 15:48Speaker 1: most transformative potential is here?
- 15:50Speaker 2: Absolutely, Rachel. The real game changer could be the democratization
- 15:55Speaker 2: of cognitive health care. Imagine a future where anyone with
- 15:58Speaker 2: a home device can access personalized neurotherapeutic treatments without the
- 16:03Speaker 2: need for frequent clinic visits. That could be a huge
- 16:06Speaker 2: shift in how we manage conditions like MCI and ADHD. Right.
- 16:10Speaker 1: And that's the crucial nuance here. The ability to provide continuous, low-cost,
- 16:15Speaker 1: and personalized treatments right in the comfort of one's home.
- 16:20Speaker 1: But let's not forget the clinical world. AI integration, like
- 16:24Speaker 1: that Dr. Paring mentioned, could take these devices to new
- 16:28Speaker 1: heights in precision medicine. Think about the potential for AI
- 16:32Speaker 1: to not just provide treatment, but to really tailor it
- 16:36Speaker 1: to the needs of each individual patient.
- 16:39Speaker 2: Exactly. That's why long-term safety and quality control will be
- 16:43Speaker 2: so critical. We have to ensure that the devices aren't
- 16:47Speaker 2: just effective, but also safe over the long term. And
- 16:51Speaker 2: the integration of AI can help with that. It can
- 16:53Speaker 2: monitor user responses and adjust the treatment in real time,
- 16:57Speaker 2: ensuring the best possible outcome. And consider the scalability aspect.
- 17:02Speaker 2: As more devices are sold and used, we will have
- 17:05Speaker 2: a wealth of data to not only continue optimizing the
- 17:08Speaker 2: technology but also to develop new treatments. This could be
- 17:12Speaker 2: a self-reinforcing mechanism where each improvement in one area spurs
- 17:16Speaker 2: innovation in another. True.
- 17:18Speaker 1: And it's important to approach this phased rollout strategy with
- 17:21Speaker 1: caution and rigor. We want to start with a small,
- 17:24Speaker 1: robust cohort to ensure the technology is sound before expanding
- 17:28Speaker 1: to a broader user base. This way, we can iron
- 17:32Speaker 1: out any kinks and ensure the highest quality of care.
- 17:36Speaker 2: Exactly. And as the devices get more affordable and reliable,
- 17:40Speaker 2: you can see a shift in how cognitive health is managed.
- 17:43Speaker 2: It's not just about traditional clinical visits, it's about managing
- 17:47Speaker 2: one's own health proactively and continuously.
- 17:49Speaker 1: Right, and that's a paradigm shift. From reactive to proactive healthcare,
- 17:55Speaker 1: leveraging technology to monitor and support our cognitive health. It's
- 18:00Speaker 1: an exciting time for both researchers and consumers alike.
- 18:03Speaker 2: Agreed. The next steps are clear, refining the technology, ensuring safety,
- 18:09Speaker 2: and integrating it into healthcare systems. But the potential for
- 18:12Speaker 2: Neuronic RLT to revolutionize how we think about and manage
- 18:16Speaker 2: cognitive health is truly groundbreaking.
- 18:19Speaker 1: That brings us to the end of today's episode. Thank
- 18:22Speaker 1: you so much for spending part of your day with me.
- 18:25Speaker 1: If you found this episode's tips helpful and want to
- 18:27Speaker 1: make sure you don't miss the next conversation, please take
- 18:31Speaker 1: a quick second to hit that subscribe or follow button
- 18:34Speaker 1: on whatever platform you are listening on. It's a completely
- 18:37Speaker 1: free way to support the show and helps more people
- 18:40Speaker 1: find us. This podcast is independently produced, so if you
- 18:44Speaker 1: are ever in a position where you would like to
- 18:46Speaker 1: help keep it running, we do accept small donations. You
- 18:49Speaker 1: can find a link right in the episode description below
- 18:52Speaker 1: to buy us a coffee or contribute. What you can,
- 18:56Speaker 1: every bit genuinely helps. Take care of yourself, stay balanced,
- 19:01Speaker 1: and we will talk again soon.